Patents Examined by Quang Nguyen
  • Patent number: 9481867
    Abstract: A method of rapidly inducing large-scale and high-purity mesenchymal stem cells to transdetermine into hematopoietic stem cells is provided with the steps of preparing homogeneous medium of mesenchymal stem cells; combining a plurality of small RNA molecules; assembling and transfecting nanoparticles of nucleic acids and polypeptides; inducing and amplifying medium of post-transdetermined hematopoietic stem cells; and activating a plurality of hemopoiesis-related genes.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: November 1, 2016
    Assignee: BEIJING GINKO BIOSCIENCE CO., LTD.
    Inventor: Qinwei Yin
  • Patent number: 9464285
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: October 11, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9458208
    Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in in vivo and in vitro environments).
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: October 4, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Ofer Yizhar, Lisa Gunaydin, Peter Hegemann, Andre Berndt
  • Patent number: 9447395
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: September 20, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9447166
    Abstract: The present invention provides an intraceptor that interacts with and decreases activity of with VEGF and/or a VEGFR for the treatment of angiogenesis-related conditions. The present invention further provides pharmaceutical compositions, and methods of use thereof, for the treatment and prevention of an angiogenesis-related condition using said intraceptors. The invention further provides for nucleic acids encoding said intraceptors.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: September 20, 2016
    Assignees: Medical College of Georgia Research Institute, University of Utah Research Foundation
    Inventors: Balamurali Ambati, Nirbhai Singh, Shivan Amin
  • Patent number: 9447164
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: September 20, 2016
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Jason P. Schrum, Stephane Bancel, Noubar B. Afeyan, Kenechi Ejebe
  • Patent number: 9447377
    Abstract: The present inventions describes a method that, starting from pluripotent cells, leads to the obtainment, in a reproducible and efficient manner, of endodermal cells precursor. These cells reveal useful also for application in the regenerative therapy.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: September 20, 2016
    Inventors: Stefania Filosa, Genesia Manganelli
  • Patent number: 9434935
    Abstract: The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.
    Type: Grant
    Filed: March 10, 2013
    Date of Patent: September 6, 2016
    Assignee: BELLICUM PHARMACEUTICALS, INC.
    Inventors: David Spencer, Wei-Chun Chang
  • Patent number: 9434781
    Abstract: The invention provides compositions and methods of treating subjects afflicted with a photoreceptor disorder. Methods for treating a subject suffering from a disorder characterized by photoreceptor cell degeneration are provided, wherein a gene encoding a photosensitive protein is introduced into a retinal cell of a subject. In one aspect of the invention, the retinal cells which receive the photosensitive protein include non-photoreceptor cells such as horizontal cells, amacrine cells, bipolar cells, and ganglion cells.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: September 6, 2016
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Richard H. Masland
  • Patent number: 9433579
    Abstract: A generally spherical growth factor sensitive vesicle bearing growth factor receptors (12) having chemical compounds (14) covalently cross-linked to their non-growth factor binding domains. The chemical compounds are capable of associating to form larger chemical compounds (16) capable of destabilizing the vesicle. Methods for treating growth factor-overexpressing neoplasms are disclosed.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: September 6, 2016
    Inventor: Albert Wong
  • Patent number: 9393323
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: July 19, 2016
    Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
  • Patent number: 9376669
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: June 28, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9359628
    Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: June 7, 2016
    Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit Gent
    Inventors: Roland Contreras, Nico L.M. Callewaert, Steven C.J. Geysens
  • Patent number: 9347073
    Abstract: Compositions and methods are provided for achieving persistent, high level expression of transgenes in vitro and in vivo. Aspects of the invention include vectors comprising an intronic cassette that comprises plasmid elements, and methods that rely on the use of vectors comprising an intronic cassette that comprises plasmid elements. These compositions and methods find use in many applications, including therapeutic applications such as in gene therapy; synthesis applications such as in the synthesis of peptides, proteins, and RNAs, e.g. for research or therapeutic purposes; and research applications, such as in the production of transgenic cells and animals. In addition, reagents, devices and kits thereof that find use in making the subject compositions and practicing the subject methods are provided.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: May 24, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior university
    Inventors: Mark A. Kay, Jiamiao Lu
  • Patent number: 9322034
    Abstract: The technology relates to a nucleic acid expression cassette comprising a TR element encoding an mRNA molecule that is translated in stressed and/or dying cells, and a nucleotide sequence operably linked to the TR element, that is a first open reading frame (ORF) sequence and encodes a polypeptide or a fragment thereof and is co-translated with the TR element. The technology further relates to mammalian cells and a transgenic animal comprising such expression cassette. Further included are kits comprising the expression cassette, and methods for determining toxicity, and killing a target cell.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: April 26, 2016
    Assignee: Wayne State University
    Inventors: Leon Carlock, Maria Cypher
  • Patent number: 9309296
    Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in vivo or in vitro environments).
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: April 12, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Ofer Yizhar, Lisa Gunaydin, Peter Hegemann, Andre Berndt
  • Patent number: 9279127
    Abstract: The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-LO) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g., antisense and RNA interfering (RNAi) molecules, targeted to a platelet-type 12-LO gene or a transcript thereof, which are capable of reducing or silencing platelet-type 12-LO expression specifically in adipocytes and pre-adipocytes. Vectors of these constructs (including, but not limited to, viral vectors), compositions of them and methods of using same for the treatment and amelioration of conditions associated with excess fat cell mass and obesity are also provided.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: March 8, 2016
    Assignee: The Medical Research Fund at the Tel-Aviv Sourasky Medical Center
    Inventors: Gary Weisinger, Rona Limor, Naftali Stern
  • Patent number: 9272004
    Abstract: Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is conjugated to a biological tissue during the sterilization process.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: March 1, 2016
    Assignee: Synovis Orthopedic and Woundcare, Inc.
    Inventors: Chandrasekaran Nataraj, Gregg Ritter, Thomas Sander
  • Patent number: 9243024
    Abstract: Disclosed are aptamer/drug conjugate complexes and the use of such complexes, together with a trigger compound, to inducibly release a drug. Also disclosed are methods for establishing a drug reservoir in a subject using these complexes, whereby drug may be released as needed. One example of such a complex is an aptamer/insulin conjugate complex from which insulin may be released by an innocuous, orally administrable trigger, such as quinine.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: January 26, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Milan N. Stojanovic, Renjun Pei, Steven Michael Forna Taylor
  • Patent number: 9206469
    Abstract: Methods and composition for nucleic acid isolation are provided. In one embodiment, a method is provided for nucleic acid purification from biological samples, such as whole blood samples, extracted with phenol-based denaturing solvents, which does not require phase separation or nucleic acid precipitation. Methods according to the invention may also be used for of small RNAs (e.g., siRNAs or miRNAs) purification and are amenable to automation.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: December 8, 2015
    Assignee: ZYMO RESEARCH CORPORATION
    Inventors: Stanislav Forman, Xiyu Jia